Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Irish healthcare firm Endo International has completed its $2.6bn acquisition of Auxilium Pharmaceuticals, following approval from the latter's shareholders and the receipt of all required regulatory approvals.
Subscribe to our email newsletter
Endo president and CEO Rajiv De Silva said: "This strategic transaction enhances the organic growth of our branded pharmaceuticals business by adding a broad range of high quality products to our already robust portfolio and expanding our development pipeline.
"We are excited to deliver on the promise of this combination by leveraging our resources to enhance the performance of Xiaflex and optimize Testopel and Stendra."
The combined company will offer an expanded platform to help accelerate the evolution and growth of Endo’s US Branded Pharmaceuticals business.
With the completion of the transaction, Endo will have access to products marketed by Auxilium including Testopel, a testosterone replacement therapy; Stendra, an erectile dysfunction treatment; and Xiaflex, a treatment for hand and urological disorders.